Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors ...

The Dec. 27, 2024, Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors opened up ...

Bristol Myers Squibb BMY announced that it has obtained a positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency for two of its drugs. The ...

Opdivo Qvantig (nivolumab and hyaluronidase ... It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Opdivo contains the medicine nivolumab. It acts on proteins on the ... Opdivo Qvantig is a subcutaneous (under-the-skin) injection in your stomach area or thigh. It is given by a healthcare ...

Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...